Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03051204 · ClinicalTrials.gov registry record
OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 175
- Enrollment target
NCT03051204: Completed study, sponsored by University of California, Los Angeles.
NCT03051204 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 175 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03051204 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 175 participants
- Enrollment target
Study Summary
Study Aims: To analyze stool specimens to test and validate the CalproLab assay against the predicate PhiCal in order to determine performance characteristics. And to correlate Calpro levels to the gut microbiome composition.
Primary Outcome
Concentration of calprotectin in stool sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2017-02-28 |
| Est. Completion | 2018-12-11 |
What the finished NCT03051204 record still lists
NCT03051204 is an observational study that tracks outcomes without assigning an intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03051204 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03051204 about?
NCT03051204 is a clinical study titled "OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome". Study Aims: To analyze stool specimens to test and validate the CalproLab assay against the predicate PhiCal in order to determine performance characteristics. And to correlate Calpro levels to the gut microbiome composition.
What is the current status of trial NCT03051204?
This trial is currently completed. The enrollment target is 175 participants. The study started on 2017-02-28. Estimated completion is 2018-12-11.
Who is sponsoring clinical trial NCT03051204?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI